Shares of Guardant Health, Inc. (GH) were rising more than 5 percent in pre-market on Monday to $34.75, after the company said its colorectal cancer screening blood test, Shield has approved by the Food and Drug Administration or FDA.
Shield is the first blood test to be approved by the FDA as a primary screening option for colorectal cancer. It is also the first blood test for CRC screening that meets the requirements for Medicare coverage, the company said in a statement.
Guardant Health stock had closed at $33, up 3.35 percent on Friday. It has traded in the range of $15.81 - $41.06 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.